Connect with us

Hi, what are you looking for?

Politics

Dr Oz to face Senate grilling on Capitol Hill in bid to run Centers for Medicare and Medicaid

Dr. Mehmet Oz, President Donald Trump’s pick to lead the Centers for Medicare and Medicaid, will face questions in front of the Senate Committee on Finance Friday morning.

Following the hearing, the committee will schedule a vote to send Oz’s nomination to the full Senate, where approval is likely, considering the Republican majority.

If confirmed, Oz would be in charge of nearly $1.5 trillion in federal healthcare spending. Medicare, a federal healthcare program for seniors aged 65 and up, currently provides coverage for about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, which assists people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov.

A former heart surgeon who saw his fame rise through his appearances on daytime TV and 13 seasons of ‘The Dr Oz Show,’ Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He ultimately lost to John Fetterman, then the state’s lieutenant governor. Oz graduated from Harvard and received medical and business degrees from the University of Pennsylvania.

Oz is expected to be grilled by Democrats during the hearing over his financial ties to a myriad of healthcare-related companies, several of which pose potential conflicts of interest for the potential CMS director.

Oz has committed to divesting many of his financial interests that pose the most obvious risk of impropriety, such as his hundreds of thousands of dollars in stock in United Health Group, a major private health insurer. He also said that if he were confirmed, he would forfeit the nearly $25 million in stock options he obtained as an advisor to a company selling health and beauty supplements.

As the administrator of CMS, Oz would make decisions related to how the government covers procedures, hospital stays and medication within the federal healthcare programs, as well as the reimbursement rates at which healthcare providers get paid for their services.

On Thursday, Trump’s pick to lead the NIH and FDA, Dr. Jay Bhattacharya and Dr. Marty Makary, respectively, were approved in committee and will now face impending votes by the full Senate.

This post appeared first on FOX NEWS
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    You May Also Like

    Sports

    Ahead of the unofficial (next Monday) and official (next Wednesday) start of NFL free agency, a massively seismic deal occurred Friday … Sorry, let...

    Sports

    Alabama’s Mark Sears didn’t have his best game of the year on Saturday. But he did hit arguably the biggest shot of the Crimson...

    Stocks

    The market sell-off continued in earnest after a brief respite on Friday. Uncertainty of geopolitical tensions and tariff talk has spooked the market and...

    Sports

    The unofficial start to NFL free agency started fast and furious. Several big-name players agreed to terms with teams. Wide receiver Chris Godwin decided...

    Disclaimer: EasyProfitResearch.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EasyProfitResearch.com | All Rights Reserved